Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs
July 25 2022 - 8:00AM
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage
pharmaceutical company with a Research & Development (R&D)
innovation engine that aims to discover, develop and ultimately
deliver impactful medicines to patients, today announced the
appointment of Harris L. Rotman, PhD, as Senior Vice President,
Regulatory Affairs.
“We are very pleased to welcome Harris to our leadership team as
we prepare for our SerpinPC program in Hemophilia B to move into
registrational studies this year and continue to steadily advance
our innovative rare disease and immuno-oncology pipeline,” said
Saurabh Saha, MD, PhD, Chief Executive Officer of Centessa.
“I’m thrilled to join the impressive team at Centessa,” said Dr.
Rotman. “This is a rare opportunity to join a company where each
program has the benefit of extraordinary R&D talent and deep
industry experience. I look forward to helping advance Centessa’s
compelling pipeline for patients with unmet needs.”
Prior to joining Centessa, Dr. Rotman served as Senior Vice
President, Head of Regulatory Affairs at SwanBio Therapeutics,
where he was responsible for managing the company’s neuromuscular
disease gene therapy programs. Dr. Rotman also previously served as
Vice President, Head of Regulatory Affairs, Branded Business at
Endo Pharmaceuticals where he led the branded global regulatory
affairs department in the US and Ireland. Earlier in his career,
Dr. Rotman held executive regulatory leadership roles with
Indivior, Shire Pharmaceuticals, Sanofi and Wyeth Pharmaceuticals.
Dr. Rotman earned his PhD in Microbiology and Molecular Virology
from Thomas Jefferson University, and a BS in Biological Sciences
from Cook College at Rutgers University.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical
company with an R&D innovation engine that aims to discover,
develop and ultimately deliver impactful medicines to patients. Our
programs span discovery-stage to late-stage development and cover a
range of high-value indications in rare diseases and
immuno-oncology. We are led by a management team with extensive
R&D experience, providing direct guidance to our program teams
to rapidly advance our candidates from research through all stages
of development. For more information, visit www.centessa.com, which
does not form part of this release.
Forward Looking Statements
This press release contains forward-looking statements. These
statements may be identified by words such as “may,” “might,”
“will,” “could,” “would,” “should,” “expect,” “intend,” “plan,”
“objective,” “anticipate,” “believe,” “estimate,” “predict,”
“potential,” “continue,” “ongoing,” “aim,” “seek,” and variations
of these words or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including statements regarding the
expected benefits of Dr. Rotman’s employment; statements concerning
the prospects of our programs; statements related to the Company’s
ability to develop our programs (including our SerpinPC program)
and deliver impactful medicines to patients; the ability of our key
executives to drive execution of the Company’s portfolio of
programs; our asset-centric business model and the intended
advantages and benefits thereof; and research and clinical
development plans and the timing thereof. Any forward-looking
statements in this press release are based on our current
expectations, estimates and projections only as of the date of this
release and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to,
risks related to the safety and tolerability profile of our product
candidates; our ability to protect and maintain our intellectual
property position; business (including commercial viability),
regulatory, economic and competitive risks, uncertainties,
contingencies and assumptions about the Company; risks inherent in
developing products and technologies; future results from our
ongoing and planned clinical trials; our ability to obtain adequate
financing, including through our financing facility with Oberland,
to fund our planned clinical trials and other expenses; trends in
the industry; the legal and regulatory framework for the industry,
including the receipt and maintenance of clearances to conduct or
continue clinical testing; future expenditures risks related to our
asset-centric corporate model; the risk that any one or more of our
product candidates will not be successfully developed and/or
commercialized; the risk that the results of preclinical studies or
clinical studies will not be predictive of future results in
connection with future studies; geo-political risks such as the
Russia-Ukraine war and risks related to the ongoing COVID-19
pandemic including the effects of the Delta, Omicron and any other
variants. These and other risks concerning our programs and
operations are described in additional detail in our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2022, and our
other reports, which are on file with the U.S. Securities and
Exchange Commission. We explicitly disclaim any obligation to
update any forward-looking statements except to the extent required
by law.
Contact:
Kristen K. Sheppard, Esq.SVP of Investor Relations
investors@centessa.com
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Oct 2023 to Oct 2024